Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ROS1 fusion |
| Therapy | Zidesamtinib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ROS1 fusion | lung non-small cell carcinoma | predicted - sensitive | Zidesamtinib | Phase I | Actionable | In a Phase I trial (ARROS-1), Zidesamtinib (NUV-520) treatment demonstrated safety and activity in patients with non-small cell lung cancer harboring a ROS1 fusion, resulting in a response rate of 38% (28/73), including a complete response in 2 patients with a duration of response of at least 16.6 mo and 23.5 mo, and median DOR was not reached (Ann Oncol (2024) 35 (Suppl_2): S804-S805; NCT05118789). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| 1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours | Full reference... |